Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Defining Baseline Mechanisms of Cefiderocol Resistance in the Enterobacterales
Patricia J. Simner, Stephan Beisken, Yehudit Bergman, et al.
Microbial Drug Resistance (2021) Vol. 28, Iss. 2, pp. 161-170
Open Access | Times Cited: 42

Showing 1-25 of 42 citing articles:

Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections
Pranita D. Tamma, Samuel L Aitken, Robert A. Bonomo, et al.
Clinical Infectious Diseases (2023)
Open Access | Times Cited: 476
Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa)
Pranita D. Tamma, Samuel L Aitken, Robert A. Bonomo, et al.
Clinical Infectious Diseases (2022) Vol. 75, Iss. 2, pp. 187-212
Open Access | Times Cited: 347
Cefiderocol: Systematic Review of Mechanisms of Resistance, Heteroresistance and In Vivo Emergence of Resistance
Stamatis Karakonstantis, Maria Rousaki, Evangelos I. Kritsotakis
Antibiotics (2022) Vol. 11, Iss. 6, pp. 723-723
Open Access | Times Cited: 147
Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections
Pranita D. Tamma, Emily L. Heil, Julie Ann Justo, et al.
Clinical Infectious Diseases (2024)
Closed Access | Times Cited: 135
New Delhi Metallo-Beta-Lactamase Facilitates the Emergence of Cefiderocol Resistance in Enterobacter cloacae
Dennis Nurjadi, Kaan Kocer, Quan Chanthalangsy, et al.
Antimicrobial Agents and Chemotherapy (2021) Vol. 66, Iss. 2
Open Access | Times Cited: 60
Cefiderocol, a Siderophore Cephalosporin, as a Treatment Option for Infections Caused by Carbapenem-Resistant Enterobacterales
Keith S. Kaye, Thierry Naas, Jason M. Pogue, et al.
Infectious Diseases and Therapy (2023) Vol. 12, Iss. 3, pp. 777-806
Open Access | Times Cited: 35
Treatment of critically ill patients with cefiderocol for infections caused by multidrug-resistant pathogens: review of the evidence
Pierluigi Viale, Christian E. Sandrock, Paula Ramírez, et al.
Annals of Intensive Care (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 29
An NDM-Producing Escherichia coli Clinical Isolate Exhibiting Resistance to Cefiderocol and the Combination of Ceftazidime-Avibactam and Aztreonam: Another Step Toward Pan-β-Lactam Resistance
Patricia J. Simner, Yehudit Bergman, Rick Conzemius, et al.
Open Forum Infectious Diseases (2023) Vol. 10, Iss. 7
Open Access | Times Cited: 27
Cefiderocol Treatment for Patients with Multidrug- and Carbapenem-Resistant Pseudomonas aeruginosa Infections in the Compassionate Use Program
Michael J. Satlin, Patricia J. Simner, Christine M Slover, et al.
Antimicrobial Agents and Chemotherapy (2023) Vol. 67, Iss. 7
Open Access | Times Cited: 24
Novel Antimicrobial Agents for Gram-Negative Pathogens
Marios Karvouniaris, Maria Panagiota Almyroudi, Mohd H. Abdul‐Aziz, et al.
Antibiotics (2023) Vol. 12, Iss. 4, pp. 761-761
Open Access | Times Cited: 23
Cefiderocol: early clinical experience for multi-drug resistant gram-negative infections
Amer El Ghali, Ashlan J. Kunz Coyne, Kristen Lucas, et al.
Microbiology Spectrum (2024) Vol. 12, Iss. 2
Open Access | Times Cited: 8
Nosocomial outbreak by NDM-1-producing Klebsiella pneumoniae highly resistant to cefiderocol, Florence, Italy, August 2021 to June 2022
Marco Coppi, Alberto Antonelli, Claudia Niccolai, et al.
Eurosurveillance (2022) Vol. 27, Iss. 43
Open Access | Times Cited: 37
Outbreak by KPC-62-producing ST307 Klebsiella pneumoniae isolates resistant to ceftazidime/avibactam and cefiderocol in a university hospital in Madrid, Spain
Juan Antonio Castillo-Polo, Marta Hernández-García, María Isabel Morosini, et al.
Journal of Antimicrobial Chemotherapy (2023) Vol. 78, Iss. 5, pp. 1259-1264
Closed Access | Times Cited: 17
An Overview of Cefiderocol’s Therapeutic Potential and Underlying Resistance Mechanisms
Sara Domingues, Tiago Lima, María José Saavedra, et al.
Life (2023) Vol. 13, Iss. 7, pp. 1427-1427
Open Access | Times Cited: 16
Six Extensively Drug-Resistant Bacteria in an Injured Soldier, Ukraine
Patrick McGann, François Lebreton, Brendan T. Jones, et al.
Emerging infectious diseases (2023) Vol. 29, Iss. 8
Open Access | Times Cited: 14
Resistance profiles of carbapenemase-producing Enterobacterales in a large centre in England: are we already losing cefiderocol?
Ioannis Baltas, Trupti Patel, A Soares
Journal of Antimicrobial Chemotherapy (2024)
Open Access | Times Cited: 5
Successful Treatment of Carbapenem-Resistant Acinetobacter baumannii Meningitis With Sulbactam-Durlobactam
Pranita D. Tamma, Shanan Immel, Sara M. Karaba, et al.
Clinical Infectious Diseases (2024)
Closed Access | Times Cited: 4
Highly adsorptive removal of cefiderocol during continuous venovenous hemodiafiltration equipped with oXiris filter in an orthotopic liver transplant recipient having septic shock caused by VIM-producing Klebsiella pneumoniae
Milo Gatti, Matteo Rinaldi, Cristiana Laici, et al.
Journal of Antimicrobial Chemotherapy (2025)
Closed Access
In Vitro Activity of Cefiderocol on Multiresistant Bacterial Strains and Genomic Analysis of Two Cefiderocol Resistant Strains
Michela Padovani, Anna Bertelli, Silvia Corbellini, et al.
Antibiotics (2023) Vol. 12, Iss. 4, pp. 785-785
Open Access | Times Cited: 12
Functional features of KPC-109, a novel 270-loop KPC-3 mutant mediating resistance to avibactam-based β-lactamase inhibitor combinations and cefiderocol
Vincenzo Di Pilato, Giulia Codda, Claudia Niccolai, et al.
International Journal of Antimicrobial Agents (2023) Vol. 63, Iss. 1, pp. 107030-107030
Closed Access | Times Cited: 11
In vitro resistance development gives insights into molecular resistance mechanisms against cefiderocol
Richard Kriz, Kathrin Spettel, Alina Pichler, et al.
The Journal of Antibiotics (2024) Vol. 77, Iss. 11, pp. 757-767
Open Access | Times Cited: 4
Human Serum Proteins and Susceptibility of Acinetobacter baumannii to Cefiderocol: Role of Iron Transport
Casin Le, Camila Pimentel, Fernando Pasterán, et al.
Biomedicines (2022) Vol. 10, Iss. 3, pp. 600-600
Open Access | Times Cited: 16
Cefiderocol: Clinical application and emergence of resistance
Liang Wang, Jie Zhu, Liang Chen, et al.
Drug Resistance Updates (2023) Vol. 72, pp. 101034-101034
Closed Access | Times Cited: 10
MultiRapid ATB NP test for detecting concomitant susceptibility and resistance of last-resort novel antibiotics available to treat multidrug-resistant Enterobacterales infections
Otávio Hallal Ferreira Raro, Maxime Bouvier, Auriane Kerbol, et al.
International Journal of Antimicrobial Agents (2024) Vol. 64, Iss. 2, pp. 107206-107206
Open Access | Times Cited: 3
Updates on the Activity, Efficacy and Emerging Mechanisms of Resistance to Cefiderocol
Gabriele Bianco, Matteo Boattini, Monica Cricca, et al.
Current Issues in Molecular Biology (2024) Vol. 46, Iss. 12, pp. 14132-14153
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top